Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GLAXF) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $2.7 billion.

  • Gsk's Net Income towards Common Stockholders rose 370357.56% to $2.7 billion in Q3 2025 from the same period last year, while for Dec 2025 it was $6.7 billion, marking a year-over-year increase of 1981.84%. This contributed to the annual value of $3.3 billion for FY2024, which is 4630.02% down from last year.
  • According to the latest figures from Q3 2025, Gsk's Net Income towards Common Stockholders is $2.7 billion, which was up 370357.56% from $1.9 billion recorded in Q2 2025.
  • Gsk's 5-year Net Income towards Common Stockholders high stood at $12.8 billion for Q3 2022, and its period low was -$75.4 million during Q3 2024.
  • In the last 5 years, Gsk's Net Income towards Common Stockholders had a median value of $1.9 billion in 2025 and averaged $2.5 billion.
  • As far as peak fluctuations go, Gsk's Net Income towards Common Stockholders plummeted by 10406.38% in 2024, and later surged by 370357.56% in 2025.
  • Over the past 5 years, Gsk's Net Income towards Common Stockholders (Quarter) stood at $1.0 billion in 2021, then skyrocketed by 206.69% to $3.1 billion in 2022, then rose by 24.82% to $3.9 billion in 2023, then fell by 26.31% to $2.8 billion in 2024, then fell by 4.65% to $2.7 billion in 2025.
  • Its Net Income towards Common Stockholders stands at $2.7 billion for Q3 2025, versus $1.9 billion for Q2 2025 and $2.0 billion for Q1 2025.